What's Happening?
Glooko, a digital health solutions provider for diabetes, has acquired Monarch Medical Technologies, known for its EndoTool Glucose Management System. This acquisition aims to unify diabetes management by integrating inpatient glycemic management with Glooko's existing outpatient capabilities. The EndoTool platform offers precise insulin dosing in real-time, reducing hypoglycemia risks and improving hospital performance. Glooko's platform aggregates data from over 200 devices, and the acquisition will enhance its ability to support both outpatient and inpatient care.
Why It's Important?
The acquisition is a strategic move to expand Glooko's connected care capabilities, addressing the critical need for effective glycemic management in hospitals, where a significant percentage of patients require insulin therapy. By integrating Monarch Medical's technology, Glooko aims to reduce hospital readmissions and improve glycemic control, benefiting patient safety and clinical outcomes. This expansion solidifies Glooko's position as a leader in digital health for diabetes management, leveraging recent investor support to enhance its platform.
What's Next?
Following the acquisition, Glooko plans to continue operating both companies' products as they currently do, while working towards a fully integrated solution. The company will focus on leveraging its recent $100M Series F financing to drive growth through product innovation and further acquisitions. This approach may lead to new developments in diabetes management technology, potentially setting new standards for care across different settings.
